Lytix Biopharma AS

Lytix Biopharma AS Net Margin

The Net Profit Margin of Lytix Biopharma AS (LYTIX.OL) as of Oct 22, 2026 is -846.64 %. In the previous year, Net Profit Margin was -2,202.38 % — a change of -61.56% (higher).

Net Margin

-846.64 %

YoY

-61.56%

Last updated:

Net Profit Margin of Lytix Biopharma AS is 2024 -846.64 % . Net Profit Margin of Lytix Biopharma AS was 2023 -2,202.38 % . It decreases by -61.56% higher compared to the previous year.

Lytix Biopharma AS's net margin stands at -846.6%, up from -1,402,933.4% several years earlier.

The Lytix Biopharma AS Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
-5,982.63 NOK
Jan 1, 2018
-18,253.71 NOK
Jan 1, 2019
-10,718.39 NOK
Jan 1, 2020
-1.40 M NOK
Jan 1, 2021
-282,641.18 NOK
Jan 1, 2022
-3,974.88 NOK
Jan 1, 2023
-2,202.38 NOK
Jan 1, 2024
-846.64 NOK
The Lytix Biopharma AS Net Margin history
YEARNet MarginYoY
-846.64 %-61.56%
-2,202.38 %-44.59%
-3,974.88 %-98.59%
-282,641.18 %-79.85%
-1.40 M %+12,989.03%
-10,718.39 %-41.28%
-18,253.71 %+205.11%
-5,982.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lytix Biopharma AS Stock analysis

What does Lytix Biopharma AS do? Lytix Biopharma AS develops novel drugs targeting resistant bacterial and fungal infections and oncology treatments. The company focuses on cancer immunotherapies that activate the patient's immune system to fight cancer by killing cancer cells, including resistant ones, and exposing their internal components to the immune system. This process generates a broad and long-lasting systemic T-cell response, overcoming tumor heterogeneity. Lytix Biopharma molecules are designed for use in various cancer indications and settings, both as mono- and combination therapies. The firm is involved in the development, marketing, and sales of pharmaceutical and biotechnology products. Lytix Biopharma AS develops cancer immunotherapies as part of its core business, leveraging its proprietary molecules that work across multiple cancer types. The company's approach enables treatment in diverse oncology settings, supporting both standalone and combined therapeutic strategies. Lytix Biopharma AS operates through the development and commercialization of its drug candidates, with an emphasis on immunotherapy solutions for resistant cancers. The company's products are positioned for use in both mono- and combination therapies across various cancer indications, targeting a broad segment of oncology patients seeking innovative treatment options. Lytix Biopharma AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lytix Biopharma AS stock

Net Profit Margin of Lytix Biopharma AS is -846.64 % in 2024.

Net Profit Margin of Lytix Biopharma AS changed from -2,202.38 % to -846.64 %, representing a -61.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Lytix Biopharma AS since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Lytix Biopharma AS with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Lytix Biopharma AS

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Lytix Biopharma AS